



Ref. No.: NLL/CS/2024-342

## Date: April 04, 2024

То

1. National Stock Exchange of India Limited Listing Department, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai 400 051 Symbol: NECLIFE

2. BSE Limited Corporate Relationship Department, P J Towers, Dalal Street, Mumbai 400 001 Scrip Code: 532649

Ref.: SEBI Circular no. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023 (read with erstwhile SEBI Circular no. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018), regarding Fund raising by issuance of Debt Securities by Large Corporate

Dear Sir/ Madam,

With reference to captioned circular, we hereby confirm you that the Nectar Lifesciences Limited is '**Not a Large Corporate'** as per the framework provided in the aforesaid circular(s) for the financial year starting from April 1, 2024 and ending on March 31, 2025.

Thanking you, Yours faithfully,

For Nectar Lifesciences Limited

(Sushil Kapoor) Chief Financial Officer (Neha Vaishnav) Company Secretary & Compliance Officer

Corporate Office : S.C.O. 38-39, Sector 9-D, Chandigarh-160 009 (India) Tel. : +91-172-3047777 Fax : +91-172-3047755 E-mail : sales@neclife.com Website : www.neclife.com CIN : L24232 PB1995 PLC 016664

Regd. Office & Works : Vill. Saidpura, Teh. Dera Bassi, Distt. Mohali (Punjab) Near Chandigarh (INDIA) Tel. : +91-1762-308000, 308001 Fax : +91-1762-281187, 308135